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CSF reduces the hematological toxicity and supportive care 
requirements in recipients of autologous and allogeneic trans- 
plants. In our staldy we combined G-CSF and GM-CSF to mobi- 
lize PBPC for transplantation. Method: A total of 21 subjects par- 
ticipated in the study. Seven patients had neuroblastoma stage IV; 
6 had stage IV Hodgkins lymphoma; 2 had second remission acute 
myeloid leukemia; 2 had third remission acute lymphoblastic 
leukemia; 1 had second relapsed rhabdomyosarcoma, and 1 with 
myelodisplastic syndrome. There were 2 normal donor children. 
All were under 18 years old. All the patients were mobilized with 
G-CSF & GM-CSF, 10ug/kg/d x 5 days each, followed by PBPC 
harvesting until a threshold of 2.0xI06/Kg CD34+ cells was 
obtained. A total of 11 autologous and 2 allogeneic PBPC trans- 
plants were performed. Results: Data on PBPC 24, 48, 72, and 
96hrs after the fifth dose of cytokines are shown in the below 
table: Six patients required 2 apheresis, 7 required 3, and 7 
required 4 apheresis to achieve our goal. For the 11 PBPC autolo 
gous transplant patients, the median days to get an 
ANC>500/mm 3 was 9.8 days; 9.5 days for the allogeneic. Median 
days to platelets engraftment was 11.5 days for the autologous 
PBPC; 12.5 for the allogeneic. None of the subjects experience 
bone pain, headache, flu like side effects or a documented o 
proven infection. Conclusions: The combination of G-CSF & 
GM-CSF (10ug/kg/day x 5 days) is well tolerated. It contrived a
clinical reduction in the degree and duration of severe neutropenia 
and thrombocytopenia in both allogeneic/autologous transplants. 
It seems to be cost effective and adequate to mobilize more than 
an average numbers of PBPC(2-3 apheresis) to perform allogene- 
ic/autologous hematopoietic ransplant in pediatric population. 
Parameter 24 48 72 96 Total 
Mean #CD34+x10exp6/kg 4.47hrs 3.87hrs 2.12hrs 1.20hrs 11,65 
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CLINICAL AND QUALITY OF LIFE MONITORING IN MULTIPLE SCLE- 
ROSIS PATIENTS UNDERGOING HIGH DOSE CHEMOTHERAPY AND 
AUTOLOGOUS STEM CELL TRANSPLANTATION 
Novik, A.AJ; IoTmva, T.I/; Lisz~kov, I.A.:; Kulag~l, A.A.:; Malysheva, 
O.A.e; Bisag~, G.N.~; 3/lelTlicheTzko, U.I'~1; Chelombit, L.f'U; Kish- 
tovich, A.I.~I; Osipova, N.EJ 1. Rassimz Cboperative Group of High 
Dose ChemotheT:apy iJ~ AuroimmuT~e Diseases, St.Petersbm'g, Rnssia~ 
Fe&ratiom 2. Russian Coopelvltive Group of High Dose Chemother~ W 
ilz ~'tlttoi77177zlt't~e Diseases, Novosibh's/e, Rltsskl~7 Federatiol~. 
High dose chemotherapy (HDCT) with autologous tem cell 
transplantation (ASCT) is a new treatment strategy for patients 
with multiple sclerosis (MS). Quality of life (QoL) is increas- 
ingly used as a treatuaent outcome along with traditional clini- 
cal outcomes. Monitoring of clinical and QoL outcomes of 
HDCT and ASCT in MS patients is worthwhile. The aim was 
to provide monitoring of clinical outcomes and QoL parame- 
ters in MS patients before and at different ime-points after 
ASCT. Seven patients with MS, who underwent HDCT and 
ASCT within Russian Cooperative Group of High Dose 
Chemotherapy in Autoiminune Diseases, were enrolled in the 
study. All the patients previously underwent conventional 
treatment. The transplantations were performed in accordance 
with EBMT protocols. MRI was carried out before APSCT 
and repeated every 6 months. QoL was assessed by Russian 
versions of QoL questionnaires: FACT-BMT - specific for 
patients with BMT, FAMS - specific for MS patients. QoL and 
EDSS evaluation were provided at baseline, at discharge, and at 
3, 6, 8, 12 months and eve W 6 months following ASCT. Fol- 
low-up period varied from 6 to 36 months (one patient - 6 
months, three patients -18 months, two patients - 24 months, 
one patient 36 months). Stabilization of the disease was 
achieved in six cases: in four patients no new lesions on MRI 
were observed, in two patients a decrease in the number of 
lesions took place. In one patient one new lesion appeared 1.5 
years after APSCT. Comparison of EDSS before ASCT and at 
follow-up revealed its decrease in 6 patients; in one patient it 
remained the same and in the patient with disease progression 
EDSS increased (from 6.5 to 7.0). Distinct QoL improvement 
was observed in all the patients with disease stabilization at the 
end of follow-up. QoL improvement on the majority of scales 
was achieved within 3 months after ASCT as compared to 
baseline with a tendency to further improvement a late follow- 
up. Definite QoL improvement was documented at one year 
after ASCT and remained stable throughout the later follow- 
up in the patients with long-term follow-up. HDCT and 
ASCT in patients with MS resulted in disease stabilization in 
six out of seven patients under observation. Along with clinical 
improvement distinct increase of QoL parameters in MS 
patients took place. 
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QUALITY OF LIFE IN PATIENTS WITH CHRONIC GRAFT VS HOST DIS- 
EASE: A QUALITY PROCESS IMPROVEMENT IN BLOOD AND MAR- 
ROW TRANSPLANTATION 
Neumam~, if.£.; Hsa, Y.; Tallarigo, ft.; ChampliJ~, R.; Coltriel, D. 
Blood and Marrow 7)'a~splmmttion, U iversity of Texas MD Anderson 
CmTcer CenTre1", HoustoT~, TX. 
Chronic Graft vs. Host Disease (cGVHD) occurs in approxi- 
mately 50% of post allogeneic blood and marrow transplantation 
(BMT) patients. The effects can be devastating to patients, who 
have survived this aggressive treatment regimen to cure or control 
their malignancies. At our comprehensive cancer center, the 
GVHD clinic MD, APN and/or PA evaluate patients with 
cGVHD referred by other BMT or community physicians. The 
clinic uses a multidisciplinary approach to provide patients com- 
prehensive assessment and treatment for the physical and psy- 
chosocial issues. During the initial assessment the patients com- 
plete the FACT-BMT (Functional Assessment of Cancer 
Therapy) and the MDASI (MD Anderson Symptom Inventory) to 
help identify quality of life (QOL) issues. The FACT-BMT is a 
50-item (0-4 scale) instrument measuring QOL with subscales 
including physical, social/family, emotional and functional wel
being as well as items, addressing BMT related issues (infertility, 
eyesight, memory, regret about BMT, cost, family hardship). 
Higher scores indicate improved the QOL. The tool developed by 
Cella has demonstrated reliability and validity. The MDASI is a 
13-iteln (0-10 scale) tool that measures ymptoms experienced. 
The outcomes data on 36 cGVHD patients who were 6 months to 
12 years post BMT indicated the following results: patients expe- 
rienced the greatest alterations in the functional, physical, and 
emotional domains. The majority (97%) experienced problems 
with skin, blurred vision (73%), hardship on family (71%), memo- 
I T (69%) and financial burden (67%). The data from the MDASI 
indicated the 5 most frequently reported symptoms to be: fatigue 
(73%), sleep disturbance (70%), sadness (70%), drowsiness (67%), 
and dry mouth (64%). With information from the QOL tools and 
comprehensive physical examination, patient referrals were expe- 
dited. Improvement in patients QOL with sequential dministra- 
tion of the tools demonstrates the importance of this GVHD mul- 
tidisciplinary clinic approach. 
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PERFORMANCE OF YOUNG LONG TERM SURVIVORS AFTER ALLO- 
GENEIC STEM CELL TRANSPLANTATION (SCT) 
Laltl-sen, H.B.; ffacobse~, N.; Heilmam~, C. Haelnatologic CliMe, 
B3/iT-mzit, Rigshospitalet, CopenhdgeJ~, Demnavk. 
Purpose: To examine overall performance of adolescents and 
young adults who have survived long" term after allo-SCT. Perfor- 
mance was estimated by means of Lansky and Karnofsk T scores. 
Patients & methods: Patients were all transplanted at the same 
BMT unit between1987 and 1997. Age at transplant was 10 to 30 
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yrs. Patients were included only if alive and in remission Sep. 
2002. Lansk T and Karnofsky scores (LK-score) as well as GvHD 
were evaluated prospectively just prior to conditioning and follow- 
ing the transplant at day 100, ly and at latest follow-up at least 
five yrs post transplant. A total of 120 patients met the inclusion 
criteria of these 56 patients (79% leukemia orMDS) survived long 
term but 4 pts were lost to follow-up. Donors consisted of HLA- 
id sib 54%, other faro. donors 15% and matched unrelated 31%. 
Results: Median LK scores were: 93% (range: 100-50%) before 
SCT, 88% (range: 100-30) day 100 (before vs. dl00 p=0.029), 
94% (range: 100-50) at ly (dl00 vs. ly: p<0.001) and 97% (range: 
100-80%) +5 yrs (ly vs. +5yrs p=0.006) after SCT. ChGvHD was 
present in 42% at ly and in 15% at +Syrs of long term smwiving 
patient. Patients transplanted with alternative donors experienced 
significant decreased LK scores: dl00 (p<0.001), ly (p=0.022) and 
+5yrs (p=0.003) compared to patients transplanted with HLA-id 
donors. Patients with chronic GvHD at ly and +5yrs had signifi- 
cantly decreased LK-score (p=0.046 and p=0.003). Conclusion: 
ChGvHD had a major impact on LK-scores. However, the major- 
ity of long term surviving young patients had a very good per- 
formance five or more years after allo SCT. Compared to pre- 
transplant 91% had an unchanged or increased LK-score. 
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QUALITY OF LIFE (QOL) AFTER ALLOGENEIC STEM CELL TRANSPLAN- 
TATION: PROSPECTIVE STUDY OF PREDICTORS OF IMPAIRED QOL 
Oka~noto, S.: Nshihira, M.; ~/Iori, T.; H?rooka, }~: Jr~ashiT~a, T.; 
Kiuchi, K.; S,~i~nura, )~; Zakeno, H.; Kondo, S. Division of Hem, atology, 
Keio University School of MedMne, Toleyo, Japan. 
The improvement in life expectancy following SCT has resulted 
in growing interests in conducting research on their QOL. This 
study prospectively measured the QOL of relatively large group of 
survivors after SCT, and assessed the factors that negatively 
affected their QOL. A total of 111 patients with malignant and 
non-malignant hematologic disorders who underwent SCT at 
Keio University Hospital from 1995 to January 2001 and survived 
without disease more than 6 months were included in this study. 
QOL was assessed by using Medical Outcome Survey-short Form 
36(SF-36), HAD-A, D (Hospital anxiety and depression scale), 
and BHS (Beck hopelessness core) starting at 6 months after 
SCT and every 6 months thereafter. The time since transplant has 
a significant influence on QOL after SCT measured by SF-36. 
The scores of both physical and social domains lower than the 
average of age-adjusted general population until one year after 
SCT except for vitality and mental health. The scores of all 
domains except for role physical and social functioning returned 
to normal by 1.5 years, and those who had survived beyond 2.5 
years are Indistinguishable from age-adjusted normal population 
and significantly better in certain domains of QOL. The scores of 
HAD and BHS remained basically unchanged after SCT. By mul- 
tiivariate analysis, those who were not married at the time of 
transplant had a significantly lower score in bodily pain, and 
women who were not working as a house wife had a significantly 
lower score of vitality, role emotional and mental health at one 
year after SCT. At 2 years after SCT, non-family member as a 
caregiver was a significant risk factor of lower scores in physical 
functioning and role physical domains. Male gender, male gender 
and family conflicts were also identified as significant risk factors 
of low scores of bodily pain and general heaith, respectively. We 
think that these data are useful to assist ransplant teams in devel- 
oping strategies to explore the nursing'intervention t  improve 
the QOL after SCT. Future study with more patients, longer fol- 
low-up, and data collecting at each t~oint after SCT is warranted 
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SYSTEMATIC REVIEW OF THE LITERATURE REGARDING FAMILY 
IMPACT WHEN AN ADULT MEMBER EXPERIENCES BONE MARROW 
TRANSPLANTATION 
Y01mg, L.K. N ,  rsi~zg, MSOE, Milv:aukee, WI; University OF Wis- 
consi~z-Madison, Madison, I/VI. 
Seventy-Five percent of bone marrow transplantions are per- 
formed on individuals 21-50 years of age, Bone/Blood cell trans- 
plantations are themselves an intensive, poissibly life threatening 
event. Best practice informs us that financial burden, extended 
absence from the family, role changes, care giver burden and 
stress are part of the impact of transplantation families. It was 
the purpose of this systematic review of literature to sunnnarize 
evidence regarding impact on families when an adult member 
receives bone marrow transplanatation. Twelve research studies 
were identified after a systematic, in-depth search was conducted. 
Four subgroups of studies included studies which addressed family 
functioning and psychological status; quality of life; family emo- 
tional expression, personality, anxiety and deprssion; and lastly, 
family caregiving. The studies varied in design. None were ran- 
domized controlled trials. Studies were from three countries. No 
study examined family interventions. Bone marrow transplanta- 
tion of adult patients indeed impacts family. In relation to psycho- 
logical well being, quality of life, family functioning and caregiv- 
ing. Children in the family expereince the impact of 
transplantation differently at differnt developmental stages. Cou- 
ples experienced martial dissatisfaction and sexual dysfunction 
although overall quality of life was satisfying. A sense of filturc 
emerged at twelve months post transplant for the falnily unit. The 
family caregiver, however, was fatigued by three months post 
tansplant, Iow family was defined in terms of sampled varied. 
None of the studies addresseed the impact on family when the 
adult member, undergoing transplant, died during or post trans- 
plantation. 
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BARRIERS TO SECOND TRANSPLANT FOR MULTIPLE MYELOMA IN A 
RANDOMIZED AUTOLOGOUS TANDEM TRIAL 
Wilson, R.L.; G~ay, M.L, Gir_alt, S. Blood and Mal~-ow Tr:aTz,rplanta- 
tio*~, Universi O, of Texas ~I.D> Anderson Cance'r Center, Hoztston, TX. 
The objective of this analysis is to identi .fy barriers to second 
transplant in multiple myeloma patients in a randomized tandem 
transplant setting. Patients were assessed from a current nmltiple 
myeloma trial at University of Texas M.D. Anderson Cancer Cen- 
ter. A total of 120 patients will be treated with an initial autolo- 
gous transplant. All patients are randomized prior to initial trans- 
plant to receive a 2nd autologous transplant with a different 
regime vs. ora] maintenance therapy if complete remission(OR) is
not achieved by day 180. Those patients that achieve CR are not 
eligible to receive the assigned treatment.To date, a total of 49 
patients have undergone initial transplant with 31 of those 
patients beyond 180 days post-initial transplant and cvaluable to 
receive the assigned treatment. Seventeen of the 31 were random- 
ized to the 2nd transplant and of theselT, 5 were in CR. The 
remaining 12 did not achieve CR and were eligible to receive the 
assigned 2nd transplant. Only 3 of the eligible 12 underwent sec- 
ond autologous transplantation.Reasons f r not proceeding with 
the planned treatment are as follows: 5 patients refused, 2 were 
denied by insurance coverage, and 2 were disqualified from study 
due to external factors. One patient was disqualified ue to inter- 
im treatment from the local physician. The final patient developed 
complications secondary to CMV pneumonia deeming him ineli- 
gible for second transplant.Regardless of the efforts made pre- 
transplant to educate the patient of the protocol requirements, 
one could speculate the reasons for patient refusal for the 2nd 
transplant. This might include length of time between transplants, 
~ime away from home, financial burden, poor initial transplant 
experience or differences between the two transplants, the 1st can 
be outpatient, and the 2nd is inpatient. Further analysis is war- 
ranted to investigate potential reasons for patient declination, 
which make up the majority of dais group at 55.56%. Insurance 
denials and disqualification account for 44.44% of non-2nd trans- 
plant participants.This analysis represents 25.83% of the total 
study population. 
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